• Moberg Pharma announced Nov. 3, 2026, that it secured a U.S. patent covering an improved dosing regimen for MOB-015.
• The patent has an expected term through December 2041.
• The U.S. grant is the first in this patent family; corresponding applications remain under examination in other markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moberg Pharma AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.